Huaming Tan

2.9k total citations
54 papers, 2.4k citations indexed

About

Huaming Tan is a scholar working on Immunology, Dermatology and Surgery. According to data from OpenAlex, Huaming Tan has authored 54 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Immunology, 20 papers in Dermatology and 9 papers in Surgery. Recurrent topics in Huaming Tan's work include Psoriasis: Treatment and Pathogenesis (22 papers), Dermatology and Skin Diseases (20 papers) and Asthma and respiratory diseases (9 papers). Huaming Tan is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (22 papers), Dermatology and Skin Diseases (20 papers) and Asthma and respiratory diseases (9 papers). Huaming Tan collaborates with scholars based in United States, Canada and Germany. Huaming Tan's co-authors include Robert Wołk, Hernán Valdez, Pankaj Gupta, Kim Papp, Alan Menter, Min Yao, Jane Harness, Kristi Chang, John M. Buatti and M. Buonanno and has published in prestigious journals such as The Lancet, Gastroenterology and Scientific Reports.

In The Last Decade

Huaming Tan

50 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Huaming Tan United States	25	1.1k	694	575	550	458	54	2.4k
Dennis Cooper United States	27	466 0.4×	229 0.3×	67 0.1×	1.1k 2.0×	176 0.4×	112	2.8k
Dok Hyun Yoon South Korea	35	721 0.7×	287 0.4×	113 0.2×	2.4k 4.3×	93 0.2×	303	4.3k
Roberto Giardini Italy	32	339 0.3×	210 0.3×	201 0.3×	1.2k 2.2×	77 0.2×	84	3.2k
Mustafa Beneklı Türkiye	24	291 0.3×	67 0.1×	156 0.3×	1.2k 2.2×	65 0.1×	182	2.6k
Jae Ho Han South Korea	28	299 0.3×	84 0.1×	95 0.2×	509 0.9×	39 0.1×	88	1.5k
E. George Elias United States	22	210 0.2×	54 0.1×	139 0.2×	760 1.4×	184 0.4×	71	1.7k
Laura C. Cappelli United States	28	481 0.4×	92 0.1×	366 0.6×	1.9k 3.5×	12 0.0×	70	2.6k
Chul Won Choi South Korea	28	220 0.2×	56 0.1×	108 0.2×	851 1.5×	49 0.1×	192	2.8k
Dusan Kotasek Australia	28	227 0.2×	37 0.1×	95 0.2×	1.2k 2.1×	73 0.2×	104	2.3k
Nicole G. Chau United States	24	193 0.2×	57 0.1×	51 0.1×	1.3k 2.3×	495 1.1×	80	2.3k

Countries citing papers authored by Huaming Tan

Since Specialization

Citations

This map shows the geographic impact of Huaming Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huaming Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huaming Tan more than expected).

Fields of papers citing papers by Huaming Tan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Huaming Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huaming Tan. The network helps show where Huaming Tan may publish in the future.

Co-authorship network of co-authors of Huaming Tan

This figure shows the co-authorship network connecting the top 25 collaborators of Huaming Tan. A scholar is included among the top collaborators of Huaming Tan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Huaming Tan. Huaming Tan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

D’Haens, Geert, Marla C. Dubinsky, Laurent Peyrin‐Biroulet, et al.. (2023). P632 Etrasimod induction therapy in moderately to severely active Crohn’s disease: results from a phase 2, randomised, double-blind substudy. Journal of Crohn s and Colitis. 17(Supplement_1). i764–i765. 14 indexed citations

Luger, Thomas A., Adelaide A. Hebert, Andrea L. Zaenglein, et al.. (2022). Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years. Pediatric Drugs. 24(2). 175–183. 13 indexed citations

Burmester, Gerd R, Peter Nash, Bruce E. Sands, et al.. (2021). Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. RMD Open. 7(2). e001595–e001595. 39 indexed citations

Callender, Valerie, Andrew Alexis, Linda Stein Gold, et al.. (2019). Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups. American Journal of Clinical Dermatology. 20(5). 711–723. 36 indexed citations

Simpson, Eric L., Gil Yosipovitch, Andrew G. Bushmakin, et al.. (2019). Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis. Acta Dermato Venereologica. 99(9). 756–761. 9 indexed citations

Winthrop, Kevin, Neil J. Korman, William Abramovits, et al.. (2018). T-cell–mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment. Journal of the American Academy of Dermatology. 78(6). 1149–1155.e1. 26 indexed citations

Winthrop, Kevin, Mark Lebwohl, Arnon D. Cohen, et al.. (2017). Herpes zoster in psoriasis patients treated with tofacitinib. Journal of the American Academy of Dermatology. 77(2). 302–309. 57 indexed citations

Armstrong, April W., et al.. (2017). Initiation, Switching, and Cessation of Psoriasis Treatments Among Patients with Moderate to Severe Psoriasis in the United States. Clinical Drug Investigation. 37(5). 493–501. 16 indexed citations

Xin, Xiaoyan, Min Li, Huaming Tan, et al.. (2016). CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis. Scientific Reports. 6(1). 32804–32804. 96 indexed citations

10.

Wu, Jashin J., Bruce Strober, Peter Riis Hansen, et al.. (2016). Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis. Journal of the American Academy of Dermatology. 75(5). 897–905. 37 indexed citations

11.

Krueger, James G., James D. Clark, Mayte Suárez‐Fariñas, et al.. (2016). Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study. Journal of Allergy and Clinical Immunology. 137(4). 1079–1090. 122 indexed citations

12.

Armstrong, April W., et al.. (2016). Under-Treatment of Patients with Moderate to Severe Psoriasis in the United States: Analysis of Medication Usage with Health Plan Data. Dermatology and Therapy. 7(1). 97–109. 47 indexed citations

13.

Papp, Kim, James G. Krueger, Steven R. Feldman, et al.. (2016). Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. Journal of the American Academy of Dermatology. 74(5). 841–850. 125 indexed citations

14.

Bachelez, H., P.C.M. van de Kerkhof, Robert Strohal, et al.. (2015). Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. The Lancet. 386(9993). 552–561. 327 indexed citations

15.

Papp, Kim, Alan Menter, Bruce Strober, et al.. (2012). Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. British Journal of Dermatology. 167(3). 668–677. 269 indexed citations

16.

Yao, Min, Pifu Luo, Henry T. Hoffman, et al.. (2007). Pathology and FDG PET Correlation of Residual Lymph Nodes in Head and Neck Cancer After Radiation Treatment. American Journal of Clinical Oncology. 30(3). 264–270. 50 indexed citations

17.

Yao, Min, Thanh Xuân Nguyễn, John M. Buatti, et al.. (2006). Changing Failure Patterns in Oropharyngeal Squamous Cell Carcinoma Treated With Intensity Modulated Radiotherapy and Implications for Future Research. American Journal of Clinical Oncology. 29(6). 606–612. 45 indexed citations

18.

Yao, Min, Nguyễn Chí Thành, Kenneth J. Dornfeld, et al.. (2005). Prognostic Significance of FDG PET for Head and Neck Cancer Treated with IMRT. International Journal of Radiation Oncology*Biology*Physics. 63. S149–S150. 1 indexed citations

19.

Yao, Min, Russell B. Smith, Michael M. Graham, et al.. (2005). The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. International Journal of Radiation Oncology*Biology*Physics. 63(4). 991–999. 137 indexed citations

20.

Yao, Min, Kenneth J. Dornfeld, John M. Buatti, et al.. (2005). Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma—the University of Iowa experience. International Journal of Radiation Oncology*Biology*Physics. 63(2). 410–421. 154 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact